<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00543075</url>
  </required_header>
  <id_info>
    <org_study_id>GPK104</org_study_id>
    <nct_id>NCT00543075</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Study of Genasense in Subjects With Normal Renal Function, Mildly Impaired Renal Function, and Moderately Impaired Renal Function</brief_title>
  <official_title>A Phase I Pharmacokinetic Study of GenasenseÂ® in Subjects With Normal Renal Function and Mildly and Moderately Impaired Renal Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genta Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genta Incorporated</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To characterize the pharmacokinetics of G3139 in subjects with normal, mildly impaired, and
      moderately impaired renal function who receive Genasense 3 mg/kg/day by continuous
      intravenous infusion for 2 days (48 hours).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2006</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">November 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics of oblimersen (G3139)</measure>
    <time_frame>Up to 58 hours after start of Genasense infusion</time_frame>
  </primary_outcome>
  <enrollment type="Actual">23</enrollment>
  <condition>Normal Renal Function</condition>
  <condition>Mildly Impaired Renal Function</condition>
  <condition>Moderately Impaired Renal Function</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Genasense (oblimersen, G3139)</intervention_name>
    <description>3 mg/kg/day by intravenous infusion for up to 48 hours</description>
    <other_name>Oblimersen</other_name>
    <other_name>G3139</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key inclusion criteria:

          -  Age &gt; 18 years

          -  Adequate organ function as determined &lt; 7 days prior to starting study medication
             (except for renal function, as specified per protocol)

          -  Creatinine clearance &gt; 80 mL/min based on the Cockcroft-Gault formula for subjects in
             Group 1; or 50 to less than or equal to 80 mL/min based on the Cockcroft-Gault formula
             and confirmed based on measured creatinine clearance for subjects in Group 2; or 30 to
             49 mL/min based on the Cockcroft-Gault formula and confirmed based on measured
             creatinine clearance for subjects in Group 3

        Key exclusion criteria:

          -  Significant medical disease

          -  Prior organ allograft

          -  Coexisting condition that would require the subject to continue therapy during the
             treatment (infusion) phase of the study with a drug known to alter renal function
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Weeks</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Harry Alcorn, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Davita Clinical Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>DaVita Clinical Research</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 10, 2007</study_first_submitted>
  <study_first_submitted_qc>October 11, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 12, 2007</study_first_posted>
  <last_update_submitted>March 11, 2012</last_update_submitted>
  <last_update_submitted_qc>March 11, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 13, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Renal Function</keyword>
  <keyword>Adult</keyword>
  <keyword>Genasense</keyword>
  <keyword>oblimersen</keyword>
  <keyword>G3139</keyword>
  <keyword>Genta</keyword>
  <keyword>Pharmacokinetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oblimersen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

